2022
A Bedside Test to Detect the Presence of Embryonic or Fetal Tissue in Vaginal Blood
Volovsky M, Ayala M, Narayanamoorthy S, Chiware T, Kotlyar A, Taylor H, Seifer D, Mor A. A Bedside Test to Detect the Presence of Embryonic or Fetal Tissue in Vaginal Blood. Obstetrics And Gynecology 2022, 140: 983-988. PMID: 36357961, DOI: 10.1097/aog.0000000000004975.Peer-Reviewed Original ResearchConceptsVaginal bloodEctopic pregnancyPositive control groupAlpha-fetoproteinControl groupFetal tissuesNegative control groupComplete miscarriageIGFBP-1Bedside testStudy groupInsulin-like growth factor-binding protein-1Growth factor-binding protein-1First-trimester bleedingProspective cohort studyRapid bedside testIntrauterine pregnancyVaginal bleedingCohort studyNonpregnant individualsReproductive-aged individualsPregnant individualsRapid test stripPregnancyMiscarriage
2015
Vitamin D Supplementation Decreases TGF-β1 Bioavailability in PCOS: A Randomized Placebo-Controlled Trial
Irani M, Seifer DB, Grazi RV, Julka N, Bhatt D, Kalgi B, Irani S, Tal O, Lambert-Messerlian G, Tal R. Vitamin D Supplementation Decreases TGF-β1 Bioavailability in PCOS: A Randomized Placebo-Controlled Trial. The Journal Of Clinical Endocrinology & Metabolism 2015, 100: 4307-4314. PMID: 26485217, DOI: 10.1210/jc.2015-2580.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAntigens, CDBiological AvailabilityCholecalciferolDehydroepiandrosterone SulfateEndoglinFemaleHumansInsulin ResistanceLipidsPolycystic Ovary SyndromeProspective StudiesReceptors, Cell SurfaceSocioeconomic FactorsTestosteroneTransforming Growth Factor beta1Vitamin DVitamin D DeficiencyVitaminsYoung AdultConceptsPolycystic ovary syndromeVD supplementationTGF-β1Clinical manifestationsClinical parametersAcademic-affiliated medical centerFerriman-Gallwey scoreOral vitamin D3Serum TGF-β1Soluble endoglin levelsPlacebo-controlled trialVitamin D supplementationTGF-β1 levelsNew treatment modalitiesD supplementationOral placeboRandomized PlaceboOvary syndromeVD levelsEndoglin levelsInsulin resistanceTreatment modalitiesMenstrual periodLipid profileVitamin D3Alpha-Fetoprotein as a Tool to Distinguish Amniotic Fluid From Urine, Vaginal Discharge, and Semen
Mor A, Tal R, Haberman S, McCalla S, Irani M, Perlman J, Seifer DB, Minkoff H. Alpha-Fetoprotein as a Tool to Distinguish Amniotic Fluid From Urine, Vaginal Discharge, and Semen. Obstetrics And Gynecology 2015, 125: 448-452. PMID: 25569004, DOI: 10.1097/aog.0000000000000635.Peer-Reviewed Original ResearchMeSH KeywordsAlpha-FetoproteinsAmniotic FluidFemaleHumansMaleProspective StudiesSemenUrineVaginal DischargeConceptsNormal vaginal dischargeAlpha-fetoprotein concentrationDiagnosis of ruptureVaginal dischargeAmniotic fluidAlpha-fetoproteinPregnant womenReceiver operator characteristic curve analysisSanitary padsOperator characteristic curve analysisProspective cohort studyAlpha-fetoprotein levelsAmniotic fluid levelsCharacteristic curve analysisAmniotic fluid specimensCohort studyInfertility evaluationMaternal urineAFP levelsFluid specimensFluid levelsSemen specimensCurve analysisUrineAFP quantification
2014
Follicular fluid placental growth factor is increased in polycystic ovarian syndrome: correlation with ovarian stimulation
Tal R, Seifer DB, Grazi RV, Malter HE. Follicular fluid placental growth factor is increased in polycystic ovarian syndrome: correlation with ovarian stimulation. Reproductive Biology And Endocrinology 2014, 12: 82. PMID: 25141961, PMCID: PMC4150963, DOI: 10.1186/1477-7827-12-82.Peer-Reviewed Original ResearchMeSH KeywordsAdultCohort StudiesDown-RegulationFamily CharacteristicsFemaleFertilization in VitroFollicular FluidHumansInfertility, FemaleInfertility, MaleMaleNew York CityOocyte RetrievalOvarian ReserveOvulation InductionPlacenta Growth FactorPolycystic Ovary SyndromePregnancyPregnancy ProteinsPregnancy RateProspective StudiesUp-RegulationVascular Endothelial Growth Factor Receptor-1ConceptsNon-PCOS controlsPCOS womenOvarian stimulationSFlt-1 levelsAnti-Mullerian hormonePlacental growth factorVascular endothelial growth factorFollicular fluidOvarian syndromeSFlt-1Growth factorSoluble receptor sFlt-1BackgroundPolycystic ovarian syndromeControlled ovarian stimulationPlGF/sFltDay of hCGProspective cohort studyPolycystic ovarian syndromeNumber of oocytesEndothelial growth factorVEGF family membersCohort studyOocyte retrievalPlGF levelsVascular changes
2008
Follicular-fluid neurotrophin levels in women undergoing assisted reproductive technology for different etiologies of infertility
Buyuk E, Seifer DB. Follicular-fluid neurotrophin levels in women undergoing assisted reproductive technology for different etiologies of infertility. Fertility And Sterility 2008, 90: 1611-1615. PMID: 18222435, DOI: 10.1016/j.fertnstert.2007.08.085.Peer-Reviewed Original ResearchConceptsMale factor infertilityDifferent etiologiesOvarian reserveNerve growth factorBDNF levelsNeurotrophin levelsBrain-derived neurotrophic factor levelsNT-3 concentrationNeurotrophic factor levelsProspective observational studyDiminished ovarian reserveHistory of endometriosisPolycystic ovarian syndromeIVF cyclesOvarian syndromeNGF levelsFollicular fluidNeurotrophin concentrationsObservational studyMAIN OUTCOMENGF concentrationsInfertilityFactor levelsEndometriosisEtiology
2007
Relationship of bariatric surgery to Müllerian-inhibiting substance levels
Merhi ZO, Minkoff H, Feldman J, Macura J, Rodriguez C, Seifer DB. Relationship of bariatric surgery to Müllerian-inhibiting substance levels. Fertility And Sterility 2007, 90: 221-224. PMID: 17727846, DOI: 10.1016/j.fertnstert.2007.05.073.Peer-Reviewed Original ResearchComparison of serum and plasma measurements of Müllerian inhibiting substance
Merhi ZO, Messerlian GM, Minkoff H, Eklund EE, Macura J, Feldman J, Rodriguez C, Seifer DB. Comparison of serum and plasma measurements of Müllerian inhibiting substance. Fertility And Sterility 2007, 89: 1836-1837. PMID: 17603056, DOI: 10.1016/j.fertnstert.2007.05.041.Peer-Reviewed Original ResearchBiologic markers of ovarian reserve and reproductive aging: application in a cohort study of HIV infection in women
Seifer DB, Golub ET, Lambert-Messerlian G, Springer G, Holman S, Moxley M, Cejtin H, Nathwani N, Anastos K, Minkoff H, Greenblatt RM. Biologic markers of ovarian reserve and reproductive aging: application in a cohort study of HIV infection in women. Fertility And Sterility 2007, 88: 1645-1652. PMID: 17418155, PMCID: PMC2682326, DOI: 10.1016/j.fertnstert.2007.01.122.Peer-Reviewed Original ResearchConceptsWomen's Interagency HIV StudyEarly follicular phaseOvarian reserveInhibin BHIV infectionMIS levelsFollicular phaseHIV StudyLower inhibin B levelsReproductive agingSerum samplesHIV infection influencesInhibin B levelsMulticenter prospective studyCross-sectional studyMenstrual cycle phaseCycle phaseUninfected womenCohort studyFSH levelsMenstrual bleedingNegative womenHIV serostatusSerum markersProspective study
2006
Effects of HIV Infection and Its Treatment on Self-Reported Menstrual Abnormalities in Women
Massad LS, Evans CT, Minkoff H, Watts DH, Greenblatt RM, Levine AM, Anastos K, Young M, Seifer DB, Golub E, Cohen M. Effects of HIV Infection and Its Treatment on Self-Reported Menstrual Abnormalities in Women. Journal Of Women's Health 2006, 15: 591-598. PMID: 16796486, DOI: 10.1089/jwh.2006.15.591.Peer-Reviewed Original ResearchMeSH KeywordsAdultAntiretroviral Therapy, Highly ActiveCD4 Lymphocyte CountComorbidityConfidence IntervalsFemaleHIV InfectionsHIV SeronegativityHIV SeropositivityHumansIncidenceMenstruation DisturbancesMulticenter Studies as TopicOdds RatioPrevalenceProspective StudiesRisk FactorsSurveys and QuestionnairesWomen's HealthConceptsHigher CD4 countsHIV-seropositive womenMenstrual abnormalitiesCD4 countHIV serostatusActive anti-retroviral therapy (HAART) useAnti-retroviral therapy useMulticenter prospective cohort studyCox proportional hazards modelProspective cohort studyHIV natural historyProportional hazards modelSeronegative womenHAART useCohort studyHIV infectionTherapy usePrevalent abnormalityMenstrual changesMenstrual problemsMost abnormalitiesNatural historyAbnormalitiesLogistic regressionWomenImmunocytochemical evidence for the presence and location of the neurotrophin–Trk receptor family in adult human preovulatory ovarian follicles
Seifer DB, Feng B, Shelden RM. Immunocytochemical evidence for the presence and location of the neurotrophin–Trk receptor family in adult human preovulatory ovarian follicles. American Journal Of Obstetrics And Gynecology 2006, 194: 1129-1134. PMID: 16580310, DOI: 10.1016/j.ajog.2005.12.022.Peer-Reviewed Original ResearchMeSH KeywordsAdultFemaleFollicular PhaseHumansImmunohistochemistryOvarian FollicleProspective StudiesReceptor, trkBConceptsHuman preovulatory folliclesTrk A receptorCumulus granulosa cellsTrk CTrk BPreovulatory folliclesOvarian folliclesGranulosa cellsFertilization/intracytoplasmic sperm injectionUnfertilized oocytesHuman ovarian folliclesA receptorsAbsence of neurotrophinsIntracytoplasmic sperm injectionPreovulatory ovarian folliclesRespective receptor proteinsReceptor proteinNT-4/5NT-3Prospective studyNeurotrophin receptorSperm injectionNeurotrophinsHuman unfertilized oocytesParacrine function
2005
Metformin reduces serum müllerian-inhibiting substance levels in women with polycystic ovary syndrome after protracted treatment
Fleming R, Harborne L, MacLaughlin DT, Ling D, Norman J, Sattar N, Seifer DB. Metformin reduces serum müllerian-inhibiting substance levels in women with polycystic ovary syndrome after protracted treatment. Fertility And Sterility 2005, 83: 130-136. PMID: 15652898, DOI: 10.1016/j.fertnstert.2004.05.098.Peer-Reviewed Original ResearchConceptsPolycystic ovary syndromeDoses of metforminObese womenOvary syndromeMenstrual frequencyMetformin treatmentHormone changesReproductive hormone changesMonths of treatmentCohort of folliclesUniversity Teaching HospitalOvarian responseOvarian functionTeaching hospitalMAIN OUTCOMEMIS concentrationsProspective treatmentSubstance levelsMetforminMonthsWomenAssessment periodTreatmentSyndromeDoses
2000
Progesterone, Inhibin, and hCG Multiple Marker Strategy to Differentiate Viable From Nonviable Pregnancies
PHIPPS M, HOGAN J, PEIPERT J, LAMBERT-MESSERLIAN G, CANICK J, SEIFER D. Progesterone, Inhibin, and hCG Multiple Marker Strategy to Differentiate Viable From Nonviable Pregnancies. Obstetrics And Gynecology 2000, 95: 227-231. DOI: 10.1097/00006250-200002000-00011.Peer-Reviewed Original ResearchMeSH KeywordsAdultBiomarkersChorionic GonadotropinChorionic Gonadotropin, beta Subunit, HumanCohort StudiesFemaleFetal ViabilityHumansInhibinsPredictive Value of TestsPregnancyPregnancy ComplicationsPregnancy OutcomePregnancy Trimester, FirstProgesteroneProspective StudiesROC CurveSensitivity and SpecificityConceptsDual-biomarker strategyMultiple biomarker strategyNonviable pregnanciesSerum progesteroneBiomarker strategiesComplaints of painProspective cohort studySymptomatic pregnant womenCombination of progesteroneCohort studyCombination of serumInhibin AUrine biomarkersFirst trimesterPregnant womenEarly gestationNonviable outcomesPregnancySingle biomarkerHCGProgesteroneSpecific biomarkersDiagnostic accuracySerum samplesBiomarkersProgesterone, inhibin, and hCG multiple marker strategy to differentiate viable from nonviable pregnancies.
Phipps M, Hogan J, Peipert J, Lambert-Messerlian G, Canick J, Seifer D. Progesterone, inhibin, and hCG multiple marker strategy to differentiate viable from nonviable pregnancies. Obstetrics And Gynecology 2000, 95: 227-31. PMID: 10674584, DOI: 10.1016/s0029-7844(99)00480-9.Peer-Reviewed Original ResearchMeSH KeywordsAdultBiomarkersChorionic GonadotropinChorionic Gonadotropin, beta Subunit, HumanCohort StudiesFemaleFetal ViabilityHumansInhibinsPredictive Value of TestsPregnancyPregnancy ComplicationsPregnancy OutcomePregnancy Trimester, FirstProgesteroneProspective StudiesROC CurveSensitivity and SpecificityConceptsDual-biomarker strategyMultiple biomarker strategyNonviable pregnanciesSerum progesteroneBiomarker strategiesComplaints of painProspective cohort studySymptomatic pregnant womenCombination of progesteroneCohort studyCombination of serumInhibin AUrine biomarkersFirst trimesterPregnant womenEarly gestationNonviable outcomesPregnancySingle biomarkerHCGProgesteroneSpecific biomarkersDiagnostic accuracySerum samplesBiomarkers
1998
Dimeric inhibin: a direct marker of ovarian aging
Danforth D, Arbogast L, Mroueh J, Kim M, Kennard E, Seifer D, Friedman C. Dimeric inhibin: a direct marker of ovarian aging. Fertility And Sterility 1998, 70: 119-123. PMID: 9660432, DOI: 10.1016/s0015-0282(98)00127-7.Peer-Reviewed Original ResearchConceptsInhibin B levelsPerimenopausal transitionOvarian reserveRegular menstrual cyclesPituitary FSH secretionDaily urine samplesSubsequent follicular phaseCorpus luteum functionYears of ageDay of ovulationWomen 39FSH levelsInhibin secretionFSH secretionPerimenopausal womenSerum levelsLH surgeProspective studyOvarian functionFollicular phaseMenstrual cycleFifth decadeMAIN OUTCOMEBlood samplesLuteal secretion
1996
Differential secretion of dimeric inhibin in cultured luteinized granulosa cells as a function of ovarian reserve
Seifer DB, Gardiner AC, Lambert-Messerlian G, Schneyer AL. Differential secretion of dimeric inhibin in cultured luteinized granulosa cells as a function of ovarian reserve. The Journal Of Clinical Endocrinology & Metabolism 1996, 81: 736-739. PMID: 8636296, DOI: 10.1210/jcem.81.2.8636296.Peer-Reviewed Original ResearchConceptsDay 3 serum FSHLuteinized granulosa cellsHigh FSH groupDimeric inhibinSerum FSHFSH groupPg/Granulosa cellsFSH levelsOvarian reserveOvulation inductionProgesterone concentrationsDay 3 serum FSH levelsCultured luteinized granulosa cellsDimeric inhibin productionLow FSH groupSerum FSH levelsFertilization-embryo transferHigher FSH levelsReproductive technology programGranulosa cell levelTotal inhibinInhibin concentrationsInhibin productionProspective study
1993
Proliferative index of human luteinized granulosa cells varies as a function of ovarian reserve
Seifer D, Charland C, Berlinsky D, Penzias A, Haning R, Naftolin F, Barker B. Proliferative index of human luteinized granulosa cells varies as a function of ovarian reserve. American Journal Of Obstetrics And Gynecology 1993, 169: 1531-1535. PMID: 8267057, DOI: 10.1016/0002-9378(93)90430-q.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgingCell DivisionFemaleFlow CytometryFollicle Stimulating HormoneFollicular PhaseGranulosa CellsHumansLinear ModelsProspective StudiesConceptsSerum follicle-stimulating hormone levelsFollicle-stimulating hormone levelsFollicle-stimulating hormoneLuteinized granulosa cellsIU/L.Ovarian reserveHormone levelsProliferative indexGranulosa cellsHormone groupChronologic agePreovulatory folliclesDay 3 follicle-stimulating hormone levelsHigh follicle-stimulating hormoneLower follicle-stimulating hormoneSerum follicle-stimulating hormoneFlow cytometryHuman luteinized granulosa cellsGreater proliferative indexSame chronologic ageWoman's ovarian reserveOvulation induction protocolsProspective cohort studyAdvanced reproductive ageIU/L
1992
Luteinizing response to human chorionic gonadotropin does not predict outcome in gonadotropin releasing hormone agonist-suppressed/human menopausal gonadotropin-stimulated in vitro fertilization (IVF) cycles
Penzias A, Shamma F, Gutmann J, Seifer D, DeCherney A, Lavy G. Luteinizing response to human chorionic gonadotropin does not predict outcome in gonadotropin releasing hormone agonist-suppressed/human menopausal gonadotropin-stimulated in vitro fertilization (IVF) cycles. Journal Of Assisted Reproduction And Genetics 1992, 9: 244-247. PMID: 1525454, DOI: 10.1007/bf01203821.Peer-Reviewed Original Research